Regeneron Pharmaceuticals (REGN) 10-K2022 FY Annual report

Filed: 6 Feb 23, 9:23am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: AB, adequacy, Adicet, Alzheimer, anticompetitive, APP, Arzneimittel, ascertaining, attend, ATTR, auditory, augment, Bausch, began, BGP, Bio, Bioeq, Biopharma, breakthrough, bundling, cadence, Cambridge, CHAPLE, Checkmate, CHMP, choose, Cimerli, Civic, CNV, college, commensurate, complication, conflict, copy, covenant, craig, cybersecurity, cyberwarfare, CytomX, decree, deeper, desensitization, diligence, dyspnea, eastern, enzyme, escalation, ethically, evacuate, evacuation, excise, exploit, fianlimab, Formycon, founder, freely, FTC, gas, German, helminth, honor, Horizon, incurrence, Incyte, inspire, invasion, IRA, kidney, Korean, lapse, linvoseltamab, Lomb, Maruho, math, mentorship, merit, microenvironment, military, Mitchga, MMO, nausea, nemolizumab, Notably, Ohio, Opzelura, outset, overcome, pace, parasitic, pathology, pattern, penalizing, perioperative, PHOTON, pilot, proportion, prove, prudent, PULSAR, pyrexia, reallocation, relocate, replenish, routine, Russia, Russian, ruxolitinib, scheme, sentence, speaking, sponsorship, STADA, stronger, student, sunset, thompson, trajectory, Transplant, Ukraine, ULC, uncovering, undertaken, undiscounted, unidentified, unpatentable, Utah, vidutolimod, violence, Virginia, visibility, vision, warfare, West, Xbrane, Ximluci

Removed: agreeing, aimed, argument, assumption, Brexit, budgeted, capable, Citibank, comment, commonly, conditionally, constrained, correlate, declaratory, denying, designee, dismissing, Division, engineered, English, estoppel, executed, exit, favored, floating, forecasting, France, Genzyme, hedged, hospitalization, initially, Interbank, Italy, jury, lesser, LIBOR, London, lowering, moot, MUFG, mutually, occupied, offered, PLC, positively, prematurity, prepayment, presidential, publication, reached, recruiting, rejecting, remanded, renewed, resorting, showing, Spain, speculative, Street, subjected, survival, swap, Tokyo, undeveloped, upheld, vacated, verdict, vicinity, Wall, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated REGN transcripts

REGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to

18 U.S.C. Section 1350,

As Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Regeneron Pharmaceuticals, Inc. (the "Company") on Form 10-K for the year ended December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Leonard S. Schleifer, M.D., Ph.D., as Principal Executive Officer of the Company, and Robert E. Landry, as Principal Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Leonard S. Schleifer
Leonard S. Schleifer, M.D., Ph.D.
President and Chief Executive Officer
(Principal Executive Officer)
February 6, 2023

/s/ Robert E. Landry
Robert E. Landry
Executive Vice President, Finance and Chief Financial Officer
(Principal Financial Officer)
February 6, 2023